Table 3.
Outcome of grade 3 or 4 toxicities in a meta-analysis comparing pemetrexed-based doublet therapy with pemetrexed alone
| Toxicity | Trials | Pemetrexed-based doublet therapy | Pemetrexed alone therapy | Heterogeneity
|
OR (95% CI) | P-value | |
|---|---|---|---|---|---|---|---|
| P | I2 | ||||||
| Grade 3–4 anemia | 7 | 43/719 | 52/737 | 0.076 | 47.5 | 0.85 (0.56–1.28) | 0.43 |
| Grade 3–4 neutropenia | 8 | 122/528 | 61/547 | 0.56 | 0 | 2.01 (1.45–2.78) | 0.00 |
| Grade 3–4 thrombocytopenia | 6 | 57/479 | 16/476 | 0.44 | 0 | 3.77 (2.16–6.59) | 0.00 |
| Grade 3–4 fatigue | 7 | 55/706 | 54/677 | 0.59 | 0 | 1.04 (0.70–1.55) | 0.59 |
| Grade 3–4 leukopenia | 7 | 65/536 | 41/515 | 0.125 | 38.3 | 1.66 (0.90–3.05) | 0.10 |
Abbreviations: OR, odds ratio; CI, confidence interval.